title: Human major histocompatibility complex contains several leukemia susceptibility genes.
abstract: In mice, homozygosity for the Mhc haplotype H-2k is associated with increased susceptibility to spontaneous and virus-induced leukemia, lymphoma and other neoplasms in the predisposed host. The influence of the Mhc on malignant development in these models is to shorten the latency after virus inoculation. Here, we present evidence that a similar phenomenon results in early-onset of human leukemia. A molecular analysis of the MHC in 112 CML patients showed that those who developed the disease when aged less than 35 years (early-onset group) had higher homozygosity rates for the DOA1, HSP70 and C4 alleles of the DR53 group of ancestral haplotypes, for a subtype of HLA-A3, and a higher allele frequency of BfFb compared to the late-onset group. The oldest patient (n = 13) homozygous for DR53 was 52-years-old (p = 0.004), and all HLA-A3 homozygous patients (n = 4) were in the early-onset group (p = 0.01). The relative risk for early-onset CML yielded by HLA-A3 homozygosity was 17.6. The well-known serological HLA-Cw4 association was not confirmed at the DNA level and thought to be due to linkage disequilibrium with BfFb. The factor B association was sex-limited. The DR52 group haplotypes appeared to be protective. The HLA-identical sibling frequency was increased only in the early-onset group (p < 0.01). Our findings agree with the concept of an MHC influence on the development of malignancies. The similarity in the location of the susceptibility loci and the serological cross-reaction between H-2Ek and DR53 raise the possibility that the mouse and human MHC share the same leukemia susceptibility genes.
authors.affiliation: Department of Haematology, University of Wales College of Medicine, Cardiff, UK.
authors.forename: M T
authors.initials: MT
authors.lastname: Dorak
authors.forename: E A
authors.initials: EA
authors.lastname: Chalmers
authors.forename: D
authors.initials: D
authors.lastname: Gaffney
authors.forename: D W
authors.initials: DW
authors.lastname: Wilson
authors.forename: I
authors.initials: I
authors.lastname: Galbraith
authors.forename: N
authors.initials: N
authors.lastname: Henderson
authors.forename: M
authors.initials: M
authors.lastname: Worwood
authors.forename: K I
authors.initials: KI
authors.lastname: Mills
authors.forename: A K
authors.initials: AK
authors.lastname: Burnett
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D002460:Cell Line; D002648:Child; D002675:Child, Preschool; D004198:Disease Susceptibility / Q000276:immunology; D020022:Genetic Predisposition to Disease; D006183:H-2 Antigens / Q000235:genetics*; D015234:HLA-A Antigens / Q000235:genetics; D015235:HLA-B Antigens / Q000235:genetics; D006681:HLA-D Antigens / Q000235:genetics; D006801:Humans; D007938:Leukemia / Q000235:genetics* / Q000276:immunology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000276:immunology; D007951:Leukemia, Myeloid / Q000235:genetics* / Q000276:immunology*; D008223:Lymphoma / Q000235:genetics / Q000276:immunology; D008285:Major Histocompatibility Complex; D008875:Middle Aged; D009369:Neoplasms / Q000235:genetics / Q000276:immunology; D009679:Nuclear Family; D012150:Polymorphism, Restriction Fragment Length; D015183:Restriction Mapping; D014407:Tumor Cells, Cultured
chemical_list: D006183:H-2 Antigens; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D006681:HLA-D Antigens